UCI 趙 Chao Family Comprehensive Cancer Center



Skin Disease-Oriented Team

Clinical Research Treatment Flowchart

Clinical Research Manager:
Mehir Tharani

Clinical Research Coordinators:
Bao-An Huynh
Natalie Arechiga
Erin Palmer-Torrison
Anastasiia Reipolska

Open to Accrual | Low Accruing | Pending Activation/Suspended

Melanoma Trials

FIRST LINE RESECTABLE

STAGE 2

EA6244
WLE + SLN biopsy vs. WLE
PI: Tran
CRC: A. Reipolska
Accrual: 3/15

FIRST LINE, STAGE 3 NEOADJUVANT + ADJUVANT

UCI 24-123
Fianlimab + Cemiplimab + Sx
(Anti-LAG-3 + anti-PD-1 antibody)
PI: Chow
CRC: TBD
Accrual: 0/35

FIRST LINE, METASTATIC OR UNRESECTABLE

UCI 25-128
Fianlimab + Cemiplimab vs. Opdualag
(Anti-LAG-3 + anti-PD-1 antibody)
PI: Vaidya
CRC: A. Reipolska
Accrual: 3/7

UVEAL

UCI 25-78
Neoadjuvant Darovasertib vs. Plaque brachytherapy or Enucleation
PI: Vaidya
CRC: B. Huynh
Accrual: 0/5

Open to Accrual | Low Accruing | Pending Activation/Suspended

Melanoma Trials

RECURRENT WITH PREVIOUS CPI

S2101
Nivolumab + Cabozantinib
(immunoMATCH: TMB + GEP)
PI: Vaidya
CRC: N. Arechiga
Accrual: 9/12

UCI 22-49
Pembrolizumab + Cyclophosphamide
(Anti-PD-1 antibody + Alkylation)
PI: Chow
CRC: B. Huynh
Accrual: 5/14

UCI 23-218
[212 Pb] VMT01 ± Nivolumab
PI: Srinivas
CRC: E. Palmer-Torrison
Accrual: 0/5

BASKET PHASE I TRIALS

UCI 24-113
BMS-686482
(CELMoD degrader IKZF transcription factors)
PI: Chow
CRC: N. Arechiga
Accrual: 5/10
(Waitlist)

UCI 24-142
VET3-TGI (recombinant virus – transgenes IL-12 + TGF-β inhibitor) ± Atezolizumab
PI: Uchio
CRC: B. Huynh
Accrual: 3/4
(Waitlist)

UCI 25-227 (Fortvita Biologics):
IBI363 +/- SOC therapy

Mechanism: PD-L1
Coord: C. Smith
PI: Dr. Arter
Accrual: 0/5
(Melanoma Cohort currently not open)

Open to Accrual | Low Accruing | Pending Activation/Suspended

Melanoma Trials

NON INTERVENTIONAL TRIALS

UCI 19-135
DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE)
PI: Yamamoto
CRC: Anastasiia R.
Accrual: 106/130

UCI 23-149
Multiphoton Microscopy Imaging as a Tool to Monitor Immune Activation Induced by Checkpoint Inhibitors
PI: Ganesan
Contact: Hira Rizwi
Accrual: 8/15

UCI 23-93
Assessment of ICOS as a Novel Biomarker to Determine Response and Resistance of Checkpoint Immunotherapy for Cutaneous Malignancies
PI: Tran
Target Accrual: 13/15

Open to Accrual | Low Accruing | Pending Activation/Suspended

BASKET PHASE I TRIALS

UCI 24-142
VET3-TGI (recombinant virus – transgenes IL-12 + TGF-β inhibitor) ± Pembrolizumab
PI: Uchio
CRC: B. Huynh
Accrual:3/4
(*Waitlist)*

Merkel Cell Trials

Cutaneous Squamous Cell Carcinoma Trials

Open to Accrual | Low Accruing | Pending Activation/Suspended

LOCALLY ADVANCED cSCC W/ PREVIOUS CPI

UCI 25-147
L19IL2 + L19TNF (Intratumoral)
PI: Yamamoto
CRC: TBD
Accrual: 0/5

BASKET PHASE I TRIALS

UCI 24-142
VET3-TGI (recombinant virus – transgenes IL-12 + TGF-β inhibitor) ± Pembrolizumab
PI: Uchio
CRC: B. Huynh
Accrual:3/4
(*Waitlist*)

Open to Accrual | Low Accruing | Pending Activation/Suspended

Other Skin Trials

INTERVENTIONAL TRIALS

UCI 24-87
Methionine-Reduced Diet
PI: Arter
CRC: K. Buttigieg
Accrual: 7/25

UCI 25-08
Laser treatment for Stage 1 BCC
(10'l nm Nd:YAG laser)
PI: Zachary
CRC: TBD
Accrual: 0/10

UCI 25-57
Neoadjuvant Opdualag vs. Nivolumab for Resectable High-Risk BCC
PI: Vaidya
CRC: A. Reipolska
Accrual: 4/10

UCI 25-127
Biofield therapy for immunotherapy-related symptoms
PI: Kagramanov
CRC: Dr. Kagramanov
Accrual: 2/12

UCI 24-05
Riluzole PO vs. Placebo PO
Perceived worsening of *cognitive function*
PI: Chan
CRC: M. Phan
Accrual: 34/59

NON-INTERVENTIONAL TRIALS

UCI 13-13
(IRB 2011-8494)
In-Vivo Non-Invasive Skin Imaging Using Multiphoton Microscopy and Multispectral Imaging
PI: Kelly
Accrual: 229/275

UCI 25-68
Understanding Barriers to Skin Cancer in AAPI
PI: Tran
Accrual: 30/75

UCI 26-102
Immune Checkpoint inhibition-related Cognitive Impairments
PI: Chan
CRC: TBD
Accrual: 0/18